» Articles » PMID: 38854407

Pseudohyponatremia: A Concise Guide to Diagnosis and Management in Clinical Practice

Overview
Journal J Nurse Pract
Publisher Elsevier
Specialty Nursing
Date 2024 Jun 10
PMID 38854407
Authors
Affiliations
Soon will be listed here.
Abstract

Pseudo-hyponatremia is an uncommon laboratory finding that can lead to serious morbidity and mortality if not recognized abruptly. Often linked to conditions like hyperlipidemia or hyperproteinemia, pseudohyponatremia can mislead clinicians and result in misdiagnosis. We discuss this through two real-world case studies, explaining how it develops and how to diagnose it accurately. It's paramount that clinicians recognize and properly differentiate pseudohyponatremia from true hyponatremia to prevent wrong treatments. We stress the need to address the root causes in order to provide the optimal patient care.

References
1.
Su L, Mittal R, Ramgobin D, Jain R, Jain R . Current Management Guidelines on Hyperlipidemia: The Silent Killer. J Lipids. 2021; 2021:9883352. PMC: 8363437. DOI: 10.1155/2021/9883352. View

2.
Kapoor P, Rajkumar S . Cardiovascular Associations With Monoclonal Gammopathy of Undetermined Significance: Real or Coincidental?. JACC CardioOncol. 2022; 4(3):323-325. PMC: 9537066. DOI: 10.1016/j.jaccao.2022.07.002. View

3.
Worthley L, Guerin M, PAIN R . For calculating osmolality, the simplest formula is the best. Anaesth Intensive Care. 1987; 15(2):199-202. DOI: 10.1177/0310057X8701500214. View

4.
Choy K, Wijeratne N, Lu Z, Doery J . Harmonisation of Osmolal Gap - Can We Use a Common Formula?. Clin Biochem Rev. 2016; 37(3):113-119. PMC: 5111243. View

5.
Moreno D, Rosinol L, Cibeira M, Blade J, Fernandez de Larrea C . Treatment of Patients with Monoclonal Gammopathy of Clinical Significance. Cancers (Basel). 2021; 13(20). PMC: 8533809. DOI: 10.3390/cancers13205131. View